Northwestern Mutual Wealth Management Co. Has $18.65 Million Stock Holdings in STERIS plc $STE

Northwestern Mutual Wealth Management Co. increased its holdings in STERIS plc (NYSE:STE) by 3,152.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 73,547 shares of the medical equipment provider’s stock after purchasing an additional 71,286 shares during the period. Northwestern Mutual Wealth Management Co. owned approximately 0.07% of STERIS worth $18,646,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its stake in STERIS by 178.6% during the third quarter. AQR Capital Management LLC now owns 1,183,070 shares of the medical equipment provider’s stock worth $291,704,000 after buying an additional 758,423 shares during the last quarter. Boston Partners bought a new stake in STERIS during the third quarter worth about $158,982,000. Orbis Allan Gray Ltd grew its stake in STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after buying an additional 556,088 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in STERIS by 246.4% during the third quarter. Thrivent Financial for Lutherans now owns 553,834 shares of the medical equipment provider’s stock worth $137,041,000 after buying an additional 393,970 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in STERIS by 16.4% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock worth $387,797,000 after buying an additional 221,199 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Stock Performance

Shares of STERIS stock opened at $214.44 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The firm has a market cap of $21.03 billion, a P/E ratio of 27.04 and a beta of 0.95. The firm has a 50 day simple moving average of $218.81 and a 200 day simple moving average of $242.57. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44.

STERIS (NYSE:STE) last issued its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same period in the prior year, the business earned $2.74 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Sell-side analysts predict that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Wall Street Analysts Forecast Growth

STE has been the topic of several research analyst reports. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday. KeyCorp decreased their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, Weiss Ratings cut shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, April 16th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $275.67.

Insider Transactions at STERIS

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the transaction, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.07% of the company’s stock.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.